Related Experiment Video

Updated: Oct 13, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.3K

Targeted Therapeutic Strategies for Triple-Negative Breast Cancer

Ying Li1,2, Zhijun Zhan1,2, Xuemin Yin1,2

  • 1Key Laboratory of Model Animals and Stem Cell Biology in Hunan Province, Department of Pathophysiology, Hunan Normal University School of Medicine, Changsha, China.

Frontiers in Oncology
|November 15, 2021
PubMed

Insights

Triple-negative breast cancer (TNBC) treatment is advancing with targeted therapies. Approved options include poly (ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors, offering new hope for patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Triple-negative breast cancer (TNBC) is an aggressive subtype lacking ER, PR, and HER2 expression.
  • Conventional chemotherapy is the primary treatment, but TNBC has a poor prognosis.
  • There is a critical need for effective molecular targeted therapies for TNBC.

Purpose of the Study:

  • To review current major developments in targeted therapies for TNBC.
  • To discuss the advantages and disadvantages of these emerging treatments.
  • To provide insights into future perspectives for TNBC targeted therapy.

Main Methods:

  • Literature review of preclinical and clinical investigations.
  • Analysis of approved and investigational targeted agents.
  • Synthesis of information on signal transduction, angiogenesis, epigenetic modifications, and cell cycle targets.

Main Results:

  • Poly (ADP-ribose) polymerase (PARP) inhibitors are approved for TNBC treatment.
  • Immune checkpoint inhibitors have also been approved for TNBC.
  • Various agents targeting signal transduction, angiogenesis, epigenetics, and cell cycle are under investigation.

Conclusions:

  • Targeted therapies represent a significant advancement in TNBC treatment.
  • PARP inhibitors and immune checkpoint inhibitors offer new therapeutic avenues.
  • Ongoing research into novel targets holds promise for improving clinical outcomes in TNBC.
Keywords:
epigenetic modificationimmune checkpointpoly (ADP-ribose) polymerasetargeted therapytriple-negative breast cancer

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.8K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

3.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
726
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K